Álvaro López-Janeiro

15PUBLICATIONS
109CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Nov 03, 2026
Complement-driven NETosis mediates immunotherapy resistance in STK11-mutant lung adenocarcinoma.

|Aug 06, 2026
Antibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors.

|Apr 14, 2026
Integrated Single-Cell and Spatial Multi-Omics of Clonal Precursors and Immune Niches in Germinal Center Lymphomas.

Sofía Huerga-Domínguez, Beñat Ariceta, Paula Aguirre-Ruiz

|Jan 16, 2026
Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.

Miguel F Sanmamed, Carlos E de Andrea, David Ruiz-Guillamon

|Nov 13, 2025
The Proteomic Landscape of CTNNB1 Mutated Low-Grade Early-Stage Endometrial Carcinomas.

Alvaro Lopez-Janeiro, Emilia Brizzi, Ignacio Ruz-Caracuel

|Oct 29, 2025
Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic.

Iñaki Eguren-Santamaria, Ignacio Melero, Inmaculada Rodríguez

Pageof 3

Frequent Collaborators

7 joint publications

Carlos E de Andrea

6 joint publications

Ignacio Melero

4 joint publications

David Hardisson

3 joint publications

Raluca Alexandru